A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors
Authors:
Kieran Mark WChi SusanGoldman StewartOnar Thomas ArzuPoussaint Tina Young + 12 more Vajapeyam SridharFahey FredericWu ShengjieTurner David CStewart Clinton FMoses MarshaPacker Roger JJakacki ReginaBanerjee AnuBoyett James MFouladi MaryamKun Larry
Source: Childs Nerv Syst 31, 1433–1445 (2015).
Date: July 19, 2015Please create a free account or log in to view this item
Registration is free, quick and easy. Simply register and complete your profile to get access. If you already have an account with the ISPN Library or ISPN Guide, login below.
Create an account
Login
Register
Log in using your ISPN Guide or ISPN Library credentials
Not yet registered? Join now









